KRMAYURVED
KRM Ayurveda financials
- Market cap
- ₹654 Cr
- Sector
- Healthcare
- Calls analysed
- 1
KRMAYURVED Q4 FY26
What went well
- Revenue from operations of ₹101.69 crore, up 32.84% YoY.
- EBITDA of ₹31.12 crore, up 62.59% YoY, with margins expanding to 30.60%.
- PAT of ₹20.12 crore, up 79.42% YoY, with PAT margins improving to 19.79%.
What KRM Ayurveda Ltd does
KRM Ayurveda began in 2019 as a kidney-specialty hospital in Delhi and has since expanded into a multi-specialty Ayurvedic healthcare group. It runs hospitals and clinics offering in-patient and out-patient Ayurvedic care, Panchakarma and other wellness therapies, staffed by BAMS-qualified physicians and certified therapists. It also manufactures classical and proprietary Ayurvedic formulations (capsules, tablets, syrups, oils) at a GMP- and ISO-certified unit in Kundli, Haryana, which it sells through a D2C/e-commerce channel and promotes via a large YouTube following, alongside teleconsultation services for patients globally.
Segments
- Hospitals & Clinics
- Product Manufacturing
- D2C, E-commerce & Telehealth
- Hospitals
- 6
- Specialty clinics
- 8
- Bed capacity
- 223 beds (as on Mar 2026)
- Average bed occupancy
- 69%
- Ayurvedic physicians
- 40+ (BAMS, CCIM-recognized)
- Manufacturing facility
- 1 GMP & ISO-certified unit (Kundli, Haryana)
Guidance record · Q4 FY26
what the last two calls moved 10 tracked 0 delivered 0 missed 10 open- Revenue Growth open said Q4 FY26 Promised: at least 50% revenue growth Q4 FY26: Therefore, we are moving ahead with a target of achieving at least 50% revenue growth.
All 10 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue down 21.2%, net profit up 81.6% against the same quarter last year.
| Line item | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 41 | 25 | 48 | 32 | 32 −21% |
| EBITDA | 8 | 6 | 13 | 11 | 12 +50% |
| Net profit | 5 | 4 | 8 | 8 | 9 +82% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +70.3% YTD
YTD: ₹180.7 on 29 Jan 2026 → ₹307.7. High ₹329.8 (10 Aug 2026), low ₹160.55 (2 Feb 2026).
How the price took the results
close before → close after
- Q4 FY26
- +8.6%
- 5 May
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹16 Cr | ₹21 Cr |
| Reserves | ₹8 Cr | ₹12 Cr | ₹21 Cr | ₹93 Cr |
| Borrowings | ₹20 Cr | ₹23 Cr | ₹25 Cr | ₹0 Cr |
| Other liabilities | ₹11 Cr | ₹9 Cr | ₹17 Cr | ₹8 Cr |
| Total liabilities | ₹39 Cr | ₹44 Cr | ₹78 Cr | ₹122 Cr |
| Fixed assets | ₹23 Cr | ₹23 Cr | ₹27 Cr | ₹26 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹38 Cr |
| Other assets | ₹16 Cr | ₹21 Cr | ₹52 Cr | ₹58 Cr |
| Total assets | ₹39 Cr | ₹44 Cr | ₹78 Cr | ₹122 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
- Promoters
- 69.2%
- FIIs
- 3.9%
- DIIs
- 3.3%
- Public
- 23.6%
Who is on the register
Named in the Mar 2026 filing
Every holder of KRM Ayurveda Ltd above SEBI's 1% disclosure line.
| Holder | Stake |
|---|---|
| Puneet Dhawan | 66.89% |
| Pine Oak Global Fund FPI fund | 2.01% |
| Mansi Share & Stock Broking Private Limited | 1.93% |
| Som Dev Dhawan | 1.27% |
| Shannon Advisors Private Limited | 1.07% |
| Aarth AIF Growth Fund AIF | 1.05% |
| Purnima Mehta | 0.53% |
| Tanya Dhawan | 0.45% |
| NBFCs registered with RBI NBFC / DFI | 0.18% |
| Puneet Dhawan Huf | 0.02% |
| Karuna Khurana | 0.01% |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 14.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse KRM Ayurveda Ltd
Guides on how to read this kind of business and the numbers that matter.